TSC Ratings provides exclusive stock, ETF and mutual fund ratings and commentary based on award-winning, proprietary tools. Its "safety first" approach to investing aims to reduce risk while seeking solid outperformance on a total return basis.

TheStreet.com Ratings upgraded Amsurg ( AMSG) to "buy." The company develops and operates ambulatory-surgery centers in partnership with U.S. physician-practice groups.

The numbers: Fiscal first-quarter revenue rose 12% to $163 million as net income climbed 7.8% to $13 million and earnings per share ascended 8.1% to 40 cents, extending a growth streak to nine quarters. The cash balance is ample with $31 million of reserves. The debt-to-equity ratio is low at 0.6. The net margin is wide at 7.7% but has shed 30 basis points since last year's first quarter.

The stock: Amsurg is down 10% in 2009, trading at a price-to-earnings ratio of about 13. The company has a market capitalization of $670 million.

TheStreet.com Ratings initiated coverage of China Bio Energy ( CBEH) at "hold." The company explores for, produces and distributes biodiesel, heavy oil and finished oil products. Roth Capital just initiated coverage as well, slapping a $9 price target and "buy" rating on the stock.

The numbers: Fiscal first-quarter revenue surged 65% as net income climbed 54% to $7.2 million and earnings per share jumped 40% to 21 cents. The company has $36 million of cash, a high quick ratio of 10, and just $2.2 million of debt. The net margin is big at 12%.

The stock: Shares of China Bio Energy are down 5% since being listed on Nasdaq. The company has a market capitalization of just $146 million.

TheStreet.com Ratings upgraded Edison International ( EIX) to "buy." Edison is a holding company for public utility California Edison and several non-utility energy companies.

If you liked this article you might like

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

'Mad Money' Lightning Round: Kroger, Dunkin' Brands

Jim Cramer's 'Mad Money' Recap: Trump Trade War Could Hit U.S. Car, Apple iPhone Sales

Analysts' Actions -- Tableau, Nucor, Pfizer, Square and More

Mednax Remains Unlikely Target as Medical Mergers Gain Steam